Acquisition Details

Gujarat Themis Biosyn Limited acquired MicroBioPharm Japan (MBJ) for a total consideration of ₹1,351 crore, which includes payment for stock options and bonus pay. The acquisition was completed on September 18, 2026.

MicroBioPharm Japan Financial Performance

MBJ reported FY26 revenue of JPY 9.5 billion (₹557 crore) with yearly EBITDA of ₹138 crore and EBITDA margin of 25%. FY25 revenue was ₹520 crore with ₹92 crore EBITDA (18% margin), and FY24 revenue was ₹568 crore with ₹113 crore EBITDA (20% margin).

Business Diversification Strategy

The acquisition marks a strategic shift from being a fermentation-based API manufacturer to becoming a fermentation-based Contract Development and Manufacturing Organization (CDMO). The company is transitioning from Anti-TB & Anti-Infective APIs to Specialty Small Molecules, Biologics & Gene therapy.

Technical Capabilities Expansion

The combined entity gains access to MBJ's technology platforms including:

  • Peptides manufacturing
  • ADC Conjugation Technology (ez-ADiCon proprietary enzyme-based technology)
  • Plasmids DNA Manufacturing (GMP-compliant)
  • Bio Conversion capabilities
  • Precision Fermentation
  • P450 Library & Process Optimization

Product Portfolio Expansion

The acquisition expands the product portfolio to include:

  • Immunosuppressants
  • Oncology products
  • Anti-Infectives
  • CDMO services for Pharma, Non-Pharma, and Biologics

Manufacturing Facilities

MBJ operates 3 GMP-compliant plants in Japan with FDA & PMDA approval track record. Gujarat Themis has one manufacturing facility in Valsad, Gujarat with annual capacity of 990 KL (expanded from 450 KL).

Customer Relationships

MBJ has long-standing customer relationships with top 8 customers accounting for over ~70% of revenue, including:

  • Customer A (ROW): 36 years total contract period
  • Customer B (Japan): 26 years
  • Customer C (Japan): 16 years
  • Customer D (ROW): 36 years
  • Customer E (Japan): 6 years
  • Customer F (Japan): 6 years
  • Customer G (ROW): 30 years
  • Customer H (Japan): 40 years

Revenue Breakdown

FY26 Revenue by Segment:

  • Contract Pharmaceuticals: Osteoporosis drugs and Arterial occlusion therapies
  • Contract Pharmaceuticals (Bio): Recombinant proteins, bio products (Carperitide, Imunace, Imunomax)
  • Proprietary Pharmaceuticals: Anthracycline Anticancer Drugs & Antibiotics
  • Developed Pharmaceuticals (Bio): Biopharmaceutical products at clinical trial stage (Gene therapy items like Plasmid)
  • Non-Pharmaceuticals: Supplements, feed formulations
  • Developed Pharmaceuticals: Investigational drug manufacturing & analytical fees

Quarterly Financial Performance (Consolidated)

Q2 FY27 Results:

  • Income from Operations: ₹49.9 crore
  • Total Expenditure: ₹50.8 crore
  • EBITDA: (₹0.9) crore with (1.8)% margin
  • Other Income: ₹3.8 crore
  • Depreciation: ₹4.5 crore
  • Interest: ₹8.4 crore
  • Exceptional Items: ₹1.2 crore (earthquake-related operational expenses at MBJ)
  • Profit Before Tax: (₹11.2) crore
  • Tax: ₹2.7 crore
  • Profit After Tax: (₹13.8) crore with (27.7)% margin
  • EPS: (₹1.06)

H1 FY27 Results:

  • Income from Operations: ₹93.7 crore
  • Total Expenditure: ₹73.8 crore
  • EBITDA: ₹19.9 crore with 21.2% margin
  • Other Income: ₹3.9 crore
  • Depreciation: ₹8.5 crore
  • Interest: ₹10.1 crore
  • Exceptional Items: ₹1.2 crore
  • Profit Before Tax: ₹4.0 crore
  • Tax: ₹6.8 crore
  • Profit After Tax: (₹2.8) crore with (3.0)% margin
  • EPS: (₹0.21)

Factors Impacting Financial Performance

The EBITDA and PAT were adversely impacted by:

1. Foreign Exchange Losses: Extraordinary unrealized foreign currency translation losses amounting to ₹15.57 crore

2. Partial-Period Consolidation: Only 13 days of MBJ revenue consolidated post-acquisition (completed September 18, 2026)

3. Exceptional Expenses: One-off, earthquake-related operational expenses of ₹1.2 crore incurred at MBJ

Company Background

Gujarat Themis Biosyn Limited was incorporated in 1981 and is India's first company to start commercial production of Antituberculosis drug Rifampicin. The company specializes in fermentation-based manufacturing with 235 employees, 1 R&D lab, and maintains 42-45% EBITDA margins.

Current Product Portfolio

  • Rifamycin Intermediates: Rifamycin S (for Rifampicin), Rifamycin O (for Rifaximin)
  • Anti-Tuberculosis APIs: Rifampicin, Rifapentine
  • Gastrointestinal API: Rifaximin